annb0t
Top 20
Recce Pharmaceuticals
Highlights:
Phase 1/2 trial of RECCE® 327 (R327) is approved to start at the South West Sydney Limb Preservation and Wound Research Unit, located at the Ingham Institute of Medical Research Study will assess the safety and efficacy of R327 on mild skin and soft tissue diabetic foot infections in up to 32 patients Patient population readily available with the first patients to be dosed in Q1 2023
SYDNEY, Australia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Recce Pharmaceutical...
>>> Read more: Recce Pharmaceuticals Receives Ethics Approval to Start Phase 1/2 Study Evaluating RECCE® 327 in Patients with Diabetic Foot Infections
Highlights:
Phase 1/2 trial of RECCE® 327 (R327) is approved to start at the South West Sydney Limb Preservation and Wound Research Unit, located at the Ingham Institute of Medical Research Study will assess the safety and efficacy of R327 on mild skin and soft tissue diabetic foot infections in up to 32 patients Patient population readily available with the first patients to be dosed in Q1 2023
SYDNEY, Australia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Recce Pharmaceutical...
>>> Read more: Recce Pharmaceuticals Receives Ethics Approval to Start Phase 1/2 Study Evaluating RECCE® 327 in Patients with Diabetic Foot Infections
